Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
Evaluate progression free survival between Pemetrexed 500 mg/m² every 3 weeks + Erlotinib 150 mg daily and Pemetrexed 500 mg/m² every 3 weeks when given as second line therapy for the treatment of locally advanced or metastatic nonsquamous Non Small Cell Lung Cancer
Critère d'inclusion
- Patients who have histologically or cytologically documented diagnosis of nonsquamous NSCLC (Stage IIIA, IIIB or IV at entry), with progressive disease after treatment with 1 prior chemotherapy regimen for locally advanced or metastatic disease, who are considered for second line therapy and who meet the other disease criteria